Syndax Pharmaceuticals (SNDX)
(Real Time Quote from BATS)
$14.87 USD
-0.58 (-3.75%)
Updated Sep 19, 2025 11:46 AM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SNDX 14.87 -0.58(-3.75%)
Will SNDX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SNDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNDX
Wall Street Analysts Believe Syndax (SNDX) Could Rally 112.8%: Here's is How to Trade
Agilent Q3 Earnings Beat Estimates, Revenues Up Y/Y, Shares Rise
SNDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect?
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates
All You Need to Know About Syndax (SNDX) Rating Upgrade to Buy
Other News for SNDX
Is SNDX signaling a buying opportunity? Pocket Pivot shows up after advancing 4.75%
SNDX: Revumenib Gains Key NCCN Recommendation for AML Treatment
Syndax announces updated NCCN Guidelines for AML
Syndax announces updated NCCN Guidelines for AML
SNDX forms Bollinger Band Squeeze on September 17